

## Reference Guide - Lab Remarks

Laboratory results are available in eChart under the Labs tab. eChart users with access to Laboratory and Report View, Clinical View, Clinical View with Images, and Clinical View with Images and Override have the ability to view these reports.

Labs may send additional information in the remarks related to the test/result such as reference ranges or comments to support the interpretation of the result. By clicking on **Remarks**, Lab Remarks will display when there is a lengthy result or lengthy comment.

### Lab Results

To view Remarks:

1. Click on the Labs tab and Laboratory to display the results for the selected patient.
2. Click on the **Collected Date** to view the test results, to view the remarks select **Remarks**.

**Name:** DENBY, COLLEEN ANNE **PHIN:** 941245741 **Age:** 44 Years **Gender:** Female

**Summary** | Encounters | Medications | **Labs** | Imaging | Pathology | Immunizations | Clinical Documents

**Lab Results** | 1 Records | Show History

Test	Result	Range	HL	Status	Facility	Remarks
Biochemistry, Drug Levels						
Vancomycin Trough	13.5 mg/L	10-20		Final	Seven Oaks General ...	<a href="#">Remarks</a>

**Labs Remarks [ Drag window border to resize ] -- Webpage Dialog**

**Remarks:** Ther. (Trough) 10-20  
 Toxic >=28  
 Target serum/plasma trough of 15 - 20 mg/L for severe documented MRSA infections.  
 Trough serum vancomycin concentrations are the most accurate and practical method for monitoring efficacy.  
 Last dose 22:00 25 Aug 20  
 Next dose 10:00 26 Aug 20  
 Collected 08:20 26 Aug 20

## Test History

To view See Remarks:

1. Click **See Remarks** to view the Lab Results History Details.

**Lab Results History Details [ Drag window border to resize ] -- Webpage Dialog**

**Test:** Triple Test      **Specimen:**

**Collected:** 29-Mar-2020 16:03      **Resulted:** 29-Mar-2020 16:03

**Facility:** Health Sciences Centre      **Status:** Final

**Result:**

```

===== TRIPLE TEST =====
          BASAL  15 min  30 min  45 min  60 min  90 min  120 min
-----
Glucose    mmol/L  3.2    3.6    4.4    6.0    8.3    3.9    5.2
Cortisol   nmol/L  164    178    213    235    264    325    642
GH         ug/L    <0.1   0.2    <0.1   <0.1   <0.1   1.3    0.8
Testosterone nmol/L  12.5
LH         IU/L    27.4   27.4   28.3   22.0   3.2    20.4   16.6
FSH        IU/L    14.3   14.6   13.8   11.5   6.0    13.9   13.0
Prolactin  ug/L    20     20     31     43     9      11     9
TSH        mIU/L   7.4    9.7    12.2   14.5   2.5    6.1    5.4
Free T4    pmol/L  18.4
Free T3    pmol/L  6.65
    
```

**REFERENCE VALUES**

Adequate hypoglycemia (glucose <2.5 mmol/L) is required for cortisol and growth hormone evaluation

Cortisol: Normal response is peak >550 nmol/L or a rise of 250 nmol/L if baseline elevated.

Growth Hormone: Normal response is peak >8 ug/L or increase of 5 ug/L over baseline.

LH: Normal response is >2 fold rise at 30 minutes.

FSH: Normal response is >50% increment.

Prolactin: Normal response is >3 fold rise (male) or >5 fold response (female) rise at 30 minutes.

## Printed Remarks

Print Preview Remarks:

1. **Print Preview** to review all pages of the printed report as remarks may be at the end of the document.

### Results

Biochemistry, Plasma/Serum						
Test	Result	Range	H/L	Status	Facility	Remarks
Hours Fasting	13 Hours		Normal	Final	Dynacare Winnipeg	
Cholesterol	2.54 mmol/L	< 5.20	Normal	Final	Dynacare Winnipeg	See (1)
(1) Please note change to reference interval, effective March 23, 2020.						
Triglyceride	2.00 mmol/L	-	Abnormal	Final	Dynacare Winnipeg	Fasting <1.70 Non fasting <2.00
Cholesterol in HDL	0.69 mmol/L	>1.00	Abnormal	Final	Dynacare Winnipeg	
Cholesterol in LDL	0.94 mmol/L	<3.50	Normal	Final	Dynacare Winnipeg	See at end of report (2)
Non-HDL Cholesterol	1.85 mmol/L	<4.30	Normal	Final	Dynacare Winnipeg	See (3)

(3)  
Reference values are based on initiation of therapy thresholds.

Therapy thresholds and targets based on Current Guidelines

10y CVD risk	Initiation of therapy	Treatment targets
High FRS >=20% Alternate:	Consider treatment in all patients	Primary: LDL-C <=2.00 mmol/L or >=50% decrease  non-HDL-C <=2.60 mmol/L
Intermediate FRS 10%-19% <2.50 mmol/L	If LDL-C >=3.50 mmol/L or LDL-C Alternate: or non-HDL-C >=4.30 mmol/L	Primary: LDL-C <=2.00 mmol/L or >=50% decrease  non-HDL-C <=2.60 mmol/L
Low FRS <10%	LDL-C >=5.00 mmol/L or familial hyperchol.	LDL-C >=50% decrease

(2) Remarks:  
Reference values are based on initiation of therapy thresholds. Calculated LDL-C is decreased if fasting is <= 10 hours; consider non-HDL-C as an alternate target in such scenarios.